National Institutes of Health logo
NIH Phase 1 Exploratory/Developmental Grant (R61)

Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61)

Funds early-stage clinical trials in arthritis, musculoskeletal and skin disease. A trial is compulsory.

OpenNational Institutes of HealthUnited States

The National Institute of Arthritis and Musculoskeletal and Skin Diseases runs this route for exploratory clinical trials in its own disease areas.

The activity code is R61, which is the first half of a phased mechanism used here on its own — exploratory work meant to establish whether a full trial is worth running.

The title carries a hard condition: a clinical trial is required. A proposal bui…

Exploratory clinical trials in arthritis, musculoskeletal and skin diseases, under the R61 phased mechanism used on its own. A clinical trial is required.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.2 Nov 2026
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.—
Funding pooliThe total budget available across all awards in this round.—

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: PAR-24-279Source: www.grants.gov